MRNA

Moderna
D

MRNA

39.360
USD
-0.20
(-0.51%)
Market Closed
Volume
444,718
EPS
-11
Div Yield
-
P/E
-7
Market Cap
15,146,429,041
OverviewSignalsIdeasNews
Signals
Related Instruments
    ABBV
    ABBV
    4.190
    (2.44%)
    175.700 USD
    AZN
    AZN
    0.950
    (1.47%)
    65.370 USD
    BMY
    BMY
    0.990
    (1.76%)
    57.280 USD
    BNTX
    BNTX
    1.810
    (1.63%)
    113.050 USD
    GSK
    GSK
    0.155
    (0.46%)
    33.595 USD
    JNJ
    JNJ
    0.890
    (0.62%)
    144.450 USD
    MRK
    MRK
    -1.390
    (-1.40%)
    98.150 USD
    N
    NVAX
    0.05000
    (0.58%)
    8.72000 USD
    PFE
    PFE
    0.595
    (2.31%)
    26.360 USD
    REGN
    REGN
    -5.64
    (-0.80%)
    702.60 USD
    More
News

Title: Moderna

Sector: Healthcare
Industry: Biotechnology
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.